期刊文献+

伏诺拉生二联疗法联合双歧杆菌三联活菌胶囊根除幽门螺杆菌的效果 被引量:1

Effect of Venolazine Combined with Bifidobacterium Triple Viable Capsule on Eradication of Helicobacter Pylori
暂未订购
导出
摘要 目的:探讨伏诺拉生二联疗法联合双歧杆菌三联活菌肠溶胶囊对幽门螺杆菌(Hp)感染患者的根治效果及安全性。方法:选取2023年1月至2023年8月漳浦县医院收治的120例Hp感染患者,根据治疗方法不同分为两组,对照组给予铋剂四联疗法,观察组给予富马酸伏诺拉生、阿莫西林胶囊及双歧杆菌三联活菌肠溶胶囊。比较两组患者治疗后的临床症状缓解率、Hp根除率、炎症指标及不良反应。结果:观察组患者的症状缓解率(98.33%)高于对照组(85.00%),Hp根除率(96.67%)高于对照组(85.00%),不良反应发生率(1.67%)低于对照组(13.33%),差异均具有统计学意义(P<0.05);观察组患者治疗14 d后的血清白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平均低于对照组,差异均具有统计学意义(P<0.05)。结论:伏诺拉生二联疗法联合双歧杆菌三联活菌肠溶胶囊治疗Hp感染的临床症状缓解率和Hp根除率较高,能有效减轻患者炎症反应,降低药物不良反应。 Objective To investigate the curative effect and safety of venolazine combined with bifidobacterium triple viable enteric capsule in the treatment of helicobacteRpylori(Hp)infection.Methods A total of 120 Hp infected patients admitted to Zhangpu County Hospital from January 2023 to August 2023 were divided into two groups according to different treatment methods.The control group was given bismuth quadruple therapy,and the observation group was given venolazine fumarate,amoxicillin capsules and bifidobacterium triple viable enteric capsule.The clinical symptom remission rate,Hp eradication rate,inflammatory indicators and adverse reactions were compared between the two groups afteRtreatment.Results The symptom remission rate(98.33%)of the observation group was higheRthan that of the control group(85.00%),the eradication rate of Hp(96.67%)was higher than that of the control group(85.00%),and the incidence of adverse reactions(1.67%)was loweRthan that of the control group(13.33%),with statistical significance(P<0.05).The levels of serum interleukin-6(IL-6)and hypersensitive C-reactive protein(hs-CRP)in the observation group were loweRthan those in the control group afteR14 days of treatment,and the differences were statistically significant(P<0.05).Conclusion The clinical symptom remission rate and eradication rate of Hp infection were higheRin the treatment of Hp infection with venolazine combined with bifidobacterium triple viable enteric capsule,which could effectively reduce the inflammatory response of patients and reduce adverse drug reactions.
作者 许秋良 陈志勇 XU Qiuliang;CHEN Zhiyong(Zhangpu County Hospital,Fujian Zhangpu 363200)
机构地区 漳浦县医院
出处 《深圳中西医结合杂志》 2024年第7期107-110,共4页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词 幽门螺杆菌感染 双歧杆菌三联活菌肠溶胶囊 伏诺拉生 阿莫西林 Helicobacter pylori infection Bifidobacterium triple viable enteric capsule Venolazine Amoxicillin
  • 相关文献

参考文献11

二级参考文献100

共引文献148

同被引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部